- Home
- STK vs ATXS Comparison
STK vs ATXS Comparison
Compare STK & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- ATXS
- Stock Information
- Founded
- STK 2009
- ATXS 2008
- Country
- STK United States
- ATXS United States
- Employees
- STK N/A
- ATXS N/A
- Industry
- STK Investment Managers
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- STK Finance
- ATXS Health Care
- Exchange
- STK Nasdaq
- ATXS Nasdaq
- Market Cap
- STK 434.6M
- ATXS 401.2M
- IPO Year
- STK N/A
- ATXS 2015
- Fundamental
- Price
- STK $30.95
- ATXS $5.81
- Analyst Decision
- STK
- ATXS Strong Buy
- Analyst Count
- STK 0
- ATXS 7
- Target Price
- STK N/A
- ATXS $32.43
- AVG Volume (30 Days)
- STK 38.2K
- ATXS 364.9K
- Earning Date
- STK 01-01-0001
- ATXS 08-11-2025
- Dividend Yield
- STK 6.60%
- ATXS N/A
- EPS Growth
- STK N/A
- ATXS N/A
- EPS
- STK N/A
- ATXS N/A
- Revenue
- STK N/A
- ATXS N/A
- Revenue This Year
- STK N/A
- ATXS N/A
- Revenue Next Year
- STK N/A
- ATXS N/A
- P/E Ratio
- STK N/A
- ATXS N/A
- Revenue Growth
- STK N/A
- ATXS N/A
- 52 Week Low
- STK $24.95
- ATXS $3.56
- 52 Week High
- STK $34.31
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- STK 74.66
- ATXS 58.38
- Support Level
- STK $30.20
- ATXS $5.26
- Resistance Level
- STK $30.89
- ATXS $5.79
- Average True Range (ATR)
- STK 0.39
- ATXS 0.38
- MACD
- STK 0.11
- ATXS -0.04
- Stochastic Oscillator
- STK 98.08
- ATXS 63.64
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.